Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07800871
PHASE1/PHASE2

FT839 in Autoimmune Diseases

Sponsor: Fate Therapeutics

View on ClinicalTrials.gov

Summary

The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.

Official title: An Open-Label, Multicenter, Phase 1/2 Dose-Escalation and Expansion Trial Evaluating the Safety and Efficacy of FT839 in Participants With Autoimmune Diseases

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

446

Start Date

2026-10

Completion Date

2040-10

Last Updated

2026-09-02

Healthy Volunteers

No

Interventions

BIOLOGICAL

FT839

Single Intravenous (IV) infusion of FT839 administered on Day 1 and Day 4

Locations (1)

Providence Medical Foundation

Fullerton, California, United States